Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

8,951 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$140.35

▲(32.29% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $140.35 with a high forecast of $169.00 and a low forecast of $122.00. The average price target represents a 32.29% change from the last price of $106.09.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"$109","170":"$170","124.25":"$124.3","139.5":"$139.5","154.75":"$154.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":169,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$169.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$122.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,124.25,139.5,154.75,170],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.658,128.06892307692308,131.47984615384615,134.89076923076922,138.30169230769232,141.7126153846154,145.12353846153846,148.53446153846153,151.94538461538463,155.3563076923077,158.76723076923076,162.17815384615386,165.58907692307693,{"y":169,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.658,125.86507692307693,127.07215384615385,128.27923076923076,129.4863076923077,130.69338461538462,131.90046153846154,133.10753846153847,134.3146153846154,135.5216923076923,136.72876923076922,137.93584615384614,139.14292307692307,{"y":140.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.658,124.45353846153846,124.24907692307693,124.04461538461538,123.84015384615385,123.63569230769231,123.43123076923077,123.22676923076924,123.02230769230769,122.81784615384615,122.61338461538462,122.40892307692307,122.20446153846154,{"y":122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110.447,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.573,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.468,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.264,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.064,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.717,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.369,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.087,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.407,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.209,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.996,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.364,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.658,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$169.00

Average Price Target$140.35

Lowest Price Target$122.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Miksic

Barclays

$169

Buy

59.30%

Upside

Reiterated

01/26/26

Abbott Laboratories (ABT) Gets a Buy from Barclays

Andrew Brackmann

William Blair

Buy

―

Reiterated

01/23/26

Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation

Adam Maeder

Piper Sandler

$150→$135

Buy

27.25%

Upside

Reiterated

01/23/26

Abbott price target lowered to $135 from $150 at Piper SandlerAbbott price target lowered to $135 from $150 at Piper Sandler

Suraj Kalia

Oppenheimer

$140→$132

Buy

24.42%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

$145

Buy

36.68%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Joanne Wuensch

Citi

$155→$140

Buy

31.96%

Upside

Reiterated

01/23/26

Abbott price target lowered to $140 from $155 at CitiAbbott price target lowered to $140 from $155 at Citi

Josh Jennings

TD Cowen

$145→$137

Buy

29.14%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Simulations Plus (NASDAQ: SLP)

Larry Biegelsen

Wells Fargo

$146→$122

Buy

15.00%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Lee Hambright

Bernstein

$154→$125

Buy

17.82%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Danielle Antalffy

UBS

$158

Buy

48.93%

Upside

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT)

Vijay Kumar

Evercore ISI

$144→$138

Buy

30.08%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Marie Thibault

BTIG

$145→$140

Buy

31.96%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Janux Therapeutics Inc (NASDAQ: JANX)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$140→$125

Hold

17.82%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Shagun Singh Chadha

RBC Capital

$147→$135

Buy

27.25%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

$150

Buy

41.39%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Miksic

Barclays

$169

Buy

59.30%

Upside

Reiterated

01/26/26

Abbott Laboratories (ABT) Gets a Buy from Barclays

Andrew Brackmann

William Blair

Buy

―

Reiterated

01/23/26

Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation

Adam Maeder

Piper Sandler

$150→$135

Buy

27.25%

Upside

Reiterated

01/23/26

Abbott price target lowered to $135 from $150 at Piper SandlerAbbott price target lowered to $135 from $150 at Piper Sandler

Suraj Kalia

Oppenheimer

$140→$132

Buy

24.42%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

$145

Buy

36.68%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Joanne Wuensch

Citi

$155→$140

Buy

31.96%

Upside

Reiterated

01/23/26

Abbott price target lowered to $140 from $155 at CitiAbbott price target lowered to $140 from $155 at Citi

Josh Jennings

TD Cowen

$145→$137

Buy

29.14%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Simulations Plus (NASDAQ: SLP)

Larry Biegelsen

Wells Fargo

$146→$122

Buy

15.00%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Lee Hambright

Bernstein

$154→$125

Buy

17.82%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Danielle Antalffy

UBS

$158

Buy

48.93%

Upside

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT)

Vijay Kumar

Evercore ISI

$144→$138

Buy

30.08%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Marie Thibault

BTIG

$145→$140

Buy

31.96%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Janux Therapeutics Inc (NASDAQ: JANX)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$140→$125

Hold

17.82%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Shagun Singh Chadha

RBC Capital

$147→$135

Buy

27.25%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

$150

Buy

41.39%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months

xxx

Success Rate

15/19 ratings generated profit

Average Return

+4.72%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +4.72% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

16/19 ratings generated profit

Average Return

+14.79%

reiterated a buy rating 9 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +14.79% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+34.85%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +34.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 47 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 140.35.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.15 with a range of $1.13 to $1.20. The previous quarter’s EPS was $1.50. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.00B with a range of $10.69B to $11.37B. The previous quarter’s sales results were $11.46B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 140.35.

What is ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 32.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABT a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s price target?

The average price target for Abbott Laboratories is 140.35. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $169.00 ,the lowest forecast is $122.00. The average price target represents 32.29% Increase from the current price of $106.09.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of ABT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Detailed List of Analyst Forecasts